29^th International Conference on Vaccines and Immunization March 19-20, 2018 London, UK

Pierre A. MORGON is the Founder of MRGN Advisors. He is Chairman of the board of Virometix and he is Non-Executive Director at the boards of Theradiag and of Eurocine Vaccines. He is also Regional Partner for Switzerland at Mérieux Development. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs.

Pharmaceutical, biological industry and in healthcare

Dr. Diaz-Mitoma is a renowned medical scientist and professor who most recently served as a professor of the Northern Ontario School of Medicine (“NOSM”). While in this position, Dr. Diaz-Mitoma was Vice President of Research at Health Sciences North and founder of the Advanced Medical Research Institute of Canada (“AMRIC”) and served as its Chief Executive Officer and Chief Scientist. AMRIC is focused on translational medical and vaccine development research. Prior to joining the faculty at the NOSM, Dr. Diaz-Mitoma was a professor of Pediatrics, Pathology, Laboratory Medicine, and Microbiology at the University of Ottawa. While in this position, he founded the Vaccine and Infectious Disease Centre at the Children’s Hospital of Eastern Ontario (“CHEO”), a pediatric health and research center. Dr. Diaz-Mitoma received his medical degree from the University of Guadalajara, completed fellowship training in Infectious Diseases at the University of Manitoba, and earned a Ph.D. in Virology from the University of Alberta.

Infectious disease, Immunology, Biotechnology

Medical and cosmopolitan professional specialized in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology and Pediatric, MBA vaccinology and years of clinical practice contributing to bring innovative science and diplomacy for global health. Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe. Speaking French, English, Russian, Italian, Czech, Slovak with notion of Mandarin. Over 15 years of experience in pharmaceutical research and development for European and USA companies (Director of R&D for new delivery platforms focused on children and elderly) for various therapeutic areas for adults and children including neurodegenerative diseases, infectious diseases, metabolic diseases and orphan indications. Active member of French immunology society (SFI) administrative board and several international academic societies (focus on innovation of R&D reflecting immunology and genetic variability, role of immunologic approach for treatment and diagnostic, tackle problem of resistance for antimicrobials, antimalarial, antivirals etc.). Member of advisory Health concern (India) and think tank group in order to attract attention to role of immunology, personalized and preventive medicine and accurate diagnostic and global cooperation in this area. Years of expertise to work globally within Europe, USA but recently more focused on BRICS - Asia (India in Particular) as a Medical advisor bringing new innovative concepts alive and getting them endorsed.

Immunology

Prof. Olga Kubar is Head of the Clinical Department at Pasteur Institute, St. Petersburg. She is an experienced Regulatory Adviser at the national and international levels (UNESCO and IPA CIS) with particular expertise on Human Rights related to medicine taking into account social, legal and environmental dimensions. Prof. Kubar has contributed to guidelines, internationally (recommendations, reports, model laws for WHO, UNESCO and IPA CIS) and is a Member of the Russian Bioethics Committee at the Commission for the Russian Federation for UNESCO, Ex-Chair and Honorary member of the Forum for Ethics Committees in the Commonwealth of Independent States (FECCIS), and a Member of the European Forum for Good Clinical Practice (EFGCP) Board.

Ethical aspects of vaccination

John D. Nieland, PhD, Associate professor, brings broad management experience, an in-depth research background in immunology and an expertise in the development of biopharmaceuticals and coordination and development of clinical trials. He worked as head of immunology and later director of research at Medigene AG, where has was involved in the development of the AAV-HPV vaccine, and held the position of vice president preclinical research at Borean Pharma. John initiated and collaborated on numerous projects, has published more than 30 articles and is the inventor of 15 patents, including several on the AAV vaccine platform. In addition to his scientific experience, John has extensive business experience and is the founder/co-founder of three biotech companies.

Immunology

J. Santiago Mejia MD, PhD is a Research Scientist interested in the development of vaccines and diagnostic platforms to help prevent and control neglected diseases.He have experience with experimental models of several arthropod-borne diseases, including: Lyme borreliosis, leishmaniasis, LaCrosse viral encephalitis, filariasis, Chagas disease and malaria. While exploring strategies to control these diseases. He became interest in arthropod saliva as potential target of pan-arthropod vaccines. He also became interested in the powerful immuno-modulatory molecules present in arthropod saliva and how they could be used in the treatment and prevention of chronic non-communicable diseases. Finally, while looking for methods to induce protective anti-salivary immunity, participated in the development of an inducible lymphoid structure (BluePort) that can be used as vaccination portal and scaffold for tissue engineering.

Development of diagnostic tests for infectious, inflammatory, autoimmune and degenerative diseases.

Dr. Ellis has over 30 years of line and senior management experience in R&D in large (including Merck), medium & small pharma and biotech companies in US & Israel – directing projects across multiple classes of indications, and directing stages from research and preclinical through development and clinical, plus project management, strategy and evaluation. He was project leader and champion for key phases in the development of five products that accrue ~$4B / year in annual sales, and brought eight product candidates to the clinic. He holds PhD (Cornell U) MBA (U Maryland), and BA (U Chicago) degrees. He has given >125 presentations at international conferences. He is founding and incumbent Editor-in-Chief of the peer-reviewed indexed journal Human Vaccines & Immunotherapeutics.

Immunotherapeutics and Vaccines

Dr. Tong-Ming Fu is a senior scientist at Merck Research Laboratories, and is leading the research lead for Merck CMV vaccine program. He obtained his medical degree at Peking University Health Science Center, formerly Beijing Medical University, in China, and his Ph.D. at Pennsylvania State University, Hershey Medical Center, in US. He joined Merck Research Laboratories after his academic trainings, and has been with Merck Vaccines Research for 20-years. He is active in many aspects of vaccine research, including vaccine target identifications, vaccine designs, immune assays, and animal model development, and his research supported development of Merck novel vaccine programs, including HIV-1 and influenza M2 peptide-conjugate vaccines. He also has research interests in DNA vaccine mechanisms, immune-enhancement by novel adjuvants and antibody-based immune modulations by PD- 1 blockade.

Infectious Diseases and Vaccines Research

Dr. Boritz began his HIV research career in the mid-1990s as a summer student in the laboratory of Dr. John K. Rose. An interest in fundamental and translational studies of host-virus interactions then led him to pursue combined M.D./Ph.D. training at University of Colorado Health Sciences Center in Denver. He completed his Ph.D. in the Immunology Program studying HIV-specific CD4 T-cell responses with Dr. Cara Wilson. After an internship and residency in Internal Medicine at Johns Hopkins Hospital, he came to NIAID as a fellow in infectious diseases. Following the clinical portion of his fellowship, he joined Dr. Daniel Douek's laboratory at Vaccine Research Center, where he worked to understand the cellular and molecular events that allow HIV reservoirs to persist in vivo. He joined the NIH faculty to establish the VPDS in 2017.

Genetic and gene expression analyses of viruses and host cells.

Prof. Liliya Pekova is a specialist of Infectious diseases and Epidemiology. She is the head of the Dept. of Infectious diseases of Medical Faculty, Trakia University, Stara Zagora, Bulgaria and a chief of the Clinic of Infectious diseases in the University Hospital at the same city. She has recently led a science project in the field of viral Neuroinfections with many different involving specialists. The accumulated great clinical experience in this area gives her reason to look for the prognostic factors and opportunities for early diagnosis and proper treatment.

Vaccines and Infectious Diseases

Natalia Romanenkova is the leading researcher of the department of virology and scientific responsible for international scientific Projects and courses in the field of virology of Pasteur Institute in Saint-Petersburg, author of more than 100 scientific publications. She is virological supervisor of WHO Subnational Laboratory for Poliomyelitis in Saint-Petersburg and expert in surveillance and diagnostics of poliomyelitis and enterovirus infections, studies of the circulation of polioviruses and non-poliomyelitis enteroviruses among population and in the environment, immunology and molecular epidemiology of viral infections. She has certificate of Appreciation of WHO Regional Office for Europe for her contribution to the success of Poliomyelitis Eradication in Russia and European Region.

Microbiology,virology,Poliomyelitis

Dr. Pramod Jog, M.D. (Ped), DNB(Ped),F.I.A.P.is Prof. of Pediatrics at D.Y.Patil Medical college, Pune, India. He has been the President of Indian Academy of Pediatrics, 2016. He is Standing Committee Member, IPA (International Pediatric Association ) 2016-19 ,Steering Committee Member, GAVI (CSO) 2016-19 & Associate Fellow, International Association of Perinatal Medicine.

Pediatrics